Azopt
(Brinzolamide)Phase 3Small molecule
NovartisThis eye drop medication is used to treat glaucoma and other eye conditions characterized by elevated pressure inside the eye, which can lead to vision problems. It works by reducing the pressure buildup in the eye.[1] Azopt is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Azopt is one of 48 small molecule programs targeting Retinopathy. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
47
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Alphagan
NovartisPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Azopt
NovartisPhase 3
Krytantek
AbbViePhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
PRO-122
LLaboratorios Sophia S.A de C.V.
Phase 3
BOL-303259-X
BBausch & Lomb Incorporated
Phase 3
Phxa41
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ocular Hypertension1 trial
Regulatory
FDA Approval Timeline[4]
Apr 1, 1998
AZOPT
NDA NDA020816
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brinzolamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]